Premium
Successful treatment of anogenital Bowen's disease with the immunomodulator imiquimod, and monitoring of therapy by DNA image cytometry
Author(s) -
Gutzmer R.,
Kaspari M.,
Vogelbruch M.,
Kiehl P.,
Kapp A.,
Werfel T.,
Brodersen JP.
Publication year - 2002
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1046/j.1365-2133.2002.04729.x
Subject(s) - imiquimod , dermatology , medicine , malignancy , bowen's disease , aneuploidy , pathology , biology , basal cell , chromosome , biochemistry , gene
Summary Imiquimod (Aldara ® , 3M) is an immune response modifier used for the treatment of anogenital warts. We report a 55‐year‐old non‐immunocompromised woman with extensive, human papillomavirus (HPV) 16‐positive anogenital Bowen's disease. After 5 months of local treatment with imiquimod, the lesions completely regressed clinically and histologically, and HPV 16 DNA was no longer detectable. Moreover, DNA image cytometry revealed DNA aneuploidy (an indicator of prospective malignancy) in pretreatment samples but not in post‐treatment samples. Therefore, imiquimod might be a treatment option for Bowen's disease, particularly in patients where other treatment modalities such as surgery are contraindicated.